Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Instant NanoBiosensors Co., Ltd. (“INB”), a developer of cutting-edge biosensor platforms designed to improve biomedical research and diagnostic processes through simple, reliable, and affordable detection solutions, today announced a collaboration between DiamiR and INB to validate INB’s automated APOE testing platform for clinical use in DiamiR’s CLIA-certified, CAP-accredited clinical laboratory.

The apolipoprotein E (APOE) gene is the strongest known genetic risk factor for late-onset Alzheimer’s disease. Individuals who carry one or two copies of the APOE ε4 allele have an increased likelihood of developing Alzheimer’s disease and may experience earlier symptom onset compared to non-carriers. APOE genetic testing is emerging as a crucial tool in the clinical management of Alzheimer’s disease, providing valuable insights into patient risk, prognosis, and treatment decision-making when used in appropriate clinical settings.

DiamiR will compare INB’s automated G8 Genotyping Analyzer for APOE testing with its New York State approved APOE test. The project will evaluate INB’s platform performance and its suitability as a potential clinical solution for Alzheimer’s disease testing within DiamiR’s CLIA-certified, CAP-accredited laboratory.

According to Alidad Mireskandari, Ph.D., Chief Executive Officer of DiamiR, “We are excited to collaborate with the INB team with the goal to introduce an automated testing solution for Alzheimer’s disease risk assessment into clinical practice. We expect that this collaboration will increase our testing capabilities and laboratory throughput.”

Tony Chung, Chairman of Instant NanoBiosensors, stated, “We view DiamiR Biosciences as a highly respected reference laboratory. We believe that completing this validation and implementing the service together will strengthen confidence in the INB platform, expand DiamiR’s validated service offerings, and establish a strong foundation for future collaboration and additional applications beyond APOE testing.”

The financial and other terms of the agreement were not disclosed.

https://www.globenewswire.com/news-release/2026/02/02/3230213/0/en/Aptorum-Group-Announces-a-Collaboration-Between-DiamiR-Biosciences-and-Instant-NanoBiosensors-INB-to-Validate-INB-s-Automated-APOE-Testing-Platform-for-Alzheimer-s-Disease.html